Noninvasive glucose monitor

Non-invasive glucose monitor
Purposemeasurement of blood glucose levels

Non-invasive glucose monitoring refers to the measurement of blood glucose levels (required by people with diabetes to prevent both chronic and acute complications from the disease) without drawing blood, puncturing the skin, or causing pain or trauma. The search for a successful technique began about 1975 and has continued to the present without a clinically or commercially viable product.[1] As of 1999, only one such product had been approved for sale by the FDA, based on a technique for electrically pulling glucose through intact skin, and it was withdrawn after a short time owing to poor performance and occasional damage to the skin of users.[2]

Hundreds of millions of dollars have been invested in companies who have sought the solution to this long-standing problem. Approaches that have been tried include near infrared spectroscopy (measuring glucose through the skin using light of slightly longer wavelengths than the visible region),[3] transdermal measurement (attempting to pull glucose through the skin using either chemicals, electricity or ultrasound), measuring the amount that polarized light is rotated by glucose in the front chamber of the eye (containing the aqueous humor), and many others. Measuring glucose through the skin presents a number of significant challenges, leading some to believe that the eye could provide the long term solution for a non-invasive glucose monitor.[4]

A 2012 study reviewed ten technologies: bioimpedance spectroscopy, microwave/RF sensing,[5][6] fluorescence technology, mid-infrared spectroscopy, near infrared spectroscopy, optical coherence tomography, optical polarimetry, raman spectroscopy, reverse iontophoresis, and ultrasound technology, concluding with the observation that none of these had produced a commercially available, clinically reliable device and that therefore, much work remained to be done.[7]

As of 2014, disregarding the severe shortcomings mentioned above, at least one non-invasive glucose meter was being marketed in a number of countries.[8][9] Still, as the mean absolute deviation of this device was nearly 30% in clinical trials, 'further research efforts were desired to significantly improve the accuracy [...]'.[10]

While multiple technologies have been tried, Raman Spectroscopy has gained traction as one promising technology for measuring glucose in interstitial fluid. Early attempts include C8 Medisensors [11] and the Laser Biomedical Research Center at MIT (Massachusetts Institute of Technology) which have been working on a Raman spectroscopy sensor for more than 20 years and conducting clinical investigations in collaboration with the Clinical Research Center at University of Missouri – Columbia.[12] In 2018 a paper in PLOS ONE showed independent validation data from a clinical investigation comprising 15 subjects with diabetes mellitus type 1 with a Mean absolute relative difference (MARD) of 25.8%.[13] The system used, was a custom-built confocal Raman setup. In 2019 researchers at the Samsung Advanced Institute of Technology (SAIT), Samsung Electronics, in collaboration with the Laser Biomedical Research Center Massachusetts Institute of Technology (MIT) developed a new approach based on Raman spectroscopy that allowed them to see the glucose signal directly. The researchers tested the system in pigs and could get accurate glucose readings for up to an hour after initial calibration.[14]

In 2020, German Institute for Diabetes-Technology have published data from 15 subjects with type 1 diabetes on a new prototype GlucoBeam based on Raman spectroscopy from RSP Systems Denmark. Showing a MARD of 23.6% on independent validation in out-patient setup with up till 8 days without recalibration.[15]

With accuracy on marketed BGM devices in the US between 5.6 and 20.8%.[16] A NIGM solution would likely need to have an accuracy with a MARD below 20% to be widely accepted.

The number of clinical trials of non-invasive glucose monitors has grown throughout the 21st century. While the National Institutes of Health recorded only 4 clinical investigations of the technology from 2000 to 2015, there were 16 from 2016 to 2020.[17]

References

  1. ↑ The Pursuit of Noninvasive Glucose, 7th Edition, by John L. Smith, Ph.D.
  2. ↑ Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO (November 1999). "Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team". JAMA. 282 (19): 1839–44. doi:10.1001/jama.282.19.1839. PMID 10573275.
  3. ↑ Ahmad M, Kamboh A, Khan A (16 October 2013). "Non-invasive blood glucose monitoring using near-infrared spectroscopy". EDN Network.
  4. ↑ annasignoretto (2021-06-04). "What makes the EYE a great way to measure blood glucose?". Occuity. Retrieved 2021-06-22.
  5. ↑ Huang SY, Yoshida Y, Inda AJ, Xavier CX, Mu WC, Meng YS, Yu W (October 2018). "Microstrip line-based glucose sensor for noninvasive continuous monitoring using the main field for sensing and multivariable crosschecking". IEEE Sensors Journal. 19 (2): 535–47. Bibcode:2019ISenJ..19..535H. doi:10.1109/JSEN.2018.2877691. S2CID 56719208.
  6. ↑ Yu W, Huang SY (October 2018). "T-Shaped Patterned Microstrip Line for Noninvasive Continuous Glucose Sensing". IEEE Microwave and Wireless Components Letters. 28 (10): 942–4. doi:10.1109/LMWC.2018.2861565. S2CID 52932653.
  7. ↑ So CF, Choi KS, Wong TK, Chung JW (June 29, 2012). "Recent advances in noninvasive glucose monitoring". Medical Devices: Evidence and Research. 5: 45–52. doi:10.2147/MDER.S28134. PMC 3500977. PMID 23166457.
  8. ↑ "Distributors | GlucoTrack".
  9. ↑ "Cnoga Medical".
  10. ↑ Vashist SK (October 2013). "Continuous Glucose Monitoring Systems: A Review". Diagnostics. 3 (4): 385–412. doi:10.3390/diagnostics3040385. PMC 4665529. PMID 26824930.
  11. ↑ Lipson J, Bernhardt J, Block U, Freeman WR, Hofmeister R, Hristakeva M, et al. (March 2009). "Requirements for calibration in noninvasive glucose monitoring by Raman spectroscopy". Journal of Diabetes Science and Technology. 3 (2): 233–41. doi:10.1177/193229680900300203. PMC 2771519. PMID 20144354.
  12. ↑ Singh SP, Mukherjee S, Galindo LH, So PT, Dasari RR, Khan UZ, et al. (October 2018). "Evaluation of accuracy dependence of Raman spectroscopic models on the ratio of calibration and validation points for non-invasive glucose sensing". Analytical and Bioanalytical Chemistry. 410 (25): 6469–6475. doi:10.1007/s00216-018-1244-y. PMC 6128756. PMID 30046865.
  13. ↑ Lundsgaard-Nielsen SM, Pors A, Banke SO, Henriksen JE, Hepp DK, Weber A (2018). "Critical-depth Raman spectroscopy enables home-use non-invasive glucose monitoring". PLOS ONE. 13 (5): e0197134. Bibcode:2018PLoSO..1397134L. doi:10.1371/journal.pone.0197134. PMC 5947912. PMID 29750797.
  14. ↑ Kang JW, Park YS, Chang H, Lee W, Singh SP, Choi W, et al. (January 2020). "Direct observation of glucose fingerprint using in vivo Raman spectroscopy". Science Advances. 6 (4): eaay5206. Bibcode:2020SciA....6.5206K. doi:10.1126/sciadv.aay5206. PMC 6981082. PMID 32042901.
  15. ↑ Pleus S, Schauer S, Jendrike N, Zschornack E, Link M, Hepp KD, et al. (August 2020). "Proof of Concept for a New Raman-Based Prototype for Noninvasive Glucose Monitoring". Journal of Diabetes Science and Technology. 15 (1): 11–18. doi:10.1177/1932296820947112. PMC 7783007. PMID 32783466.
  16. ↑ Ekhlaspour L, Mondesir D, Lautsch N, Balliro C, Hillard M, Magyar K, et al. (May 2017). "Comparative Accuracy of 17 Point-of-Care Glucose Meters". Journal of Diabetes Science and Technology. 11 (3): 558–566. doi:10.1177/1932296816672237. PMC 5505415. PMID 27697848.
  17. ↑ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2020-08-28.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.